Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

Oncologist. 2007 Mar;12(3):325-30. doi: 10.1634/theoncologist.12-3-325.

Abstract

Inhibiting epidermal growth factor receptor (EGFR) signaling has proven to be an effective strategy for treating non-small cell lung cancer (NSCLC) patients and the first generation of agents developed for this purpose, gefitinib and erlotinib, stimulated a unique escalation in both biologic and clinical research within the field. Second-generation EGFR-targeted agents that aim to further improve patient outcomes are now in preclinical and clinical trials. This review discusses four promising agents that are currently being studied in NSCLC: EKB-569, HKI-272, CI-1033, and ZD6474.

Publication types

  • Review

MeSH terms

  • Aminoquinolines
  • Aniline Compounds
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • ErbB Receptors / antagonists & inhibitors*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Morpholines / therapeutic use
  • Organic Chemicals / therapeutic use
  • Piperidines / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use*
  • Quinazolines / therapeutic use
  • Quinolines / therapeutic use

Substances

  • Aminoquinolines
  • Aniline Compounds
  • Antineoplastic Agents
  • Morpholines
  • Organic Chemicals
  • Piperidines
  • Protein Kinase Inhibitors
  • Quinazolines
  • Quinolines
  • Canertinib
  • ErbB Receptors
  • neratinib
  • EKB 569
  • vandetanib